

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|------------------|---|---------------------|-----------------|
| Application of: | Crooke et al. | Confirmation No.: | 6604 |
| Application No.: | 10/553,722 | Art Unit: | 1635 |
| Filed: | July 10, 2006 | Examiner: | Gibbs, Terra C. |
| For: | MODULATION OF APOLIPOPROTEIN C-III EXPRESSION | Attorney Docket No: | BIOL0004USA |

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to M.P.E.P. §713.04, and in response to the Interview Summary, mailed July 15, 2009, Applicants submit the following Statement of the Substance of the Interview with the Examiner conducted by telephone on July 14, 2009. Present at the Interview were Examiner Gibbs, Applicants' representatives Teresa Liang and David Pauling, and a technical expert, Richard Lee.

Applicants confirm that Examiner Gibbs' Interview Summary, mailed July 15, 2009, provides an accurate written summary of the Substance of the Interview, in that the application of the prior art cited in the obviousness rejection to the claims was discussed. In particular, Dr. Lee and Applicants' representatives explained that the Schacter *et al.* and Jong *et al.* references relate to effects of apolipoprotein C-III on plasma triglyceride concentrations rather than liver triglyceride concentrations. Dr. Lee further pointed out that, given the knowledge in the art regarding the mechanism of action of apolipoprotein C-III, a reduction of plasma triglyceride levels would not necessarily correlate with a reduction in liver triglyceride levels.

The Examiner further invited Applicants to submit references that suggest that reduction of plasma triglyceride concentrations, particularly by agents that, *inter alia*, modulate apolipoprotein C-III, do not necessarily correlate with a reduction in liver triglyceride

concentrations. Accordingly, Applicants file herewith an Information Disclosure Statement with two such references.

No fees are believed to be due in connection with the filing of this Statement. However, the Commissioner is hereby authorized to charge any required fee(s) to Jones Day Deposit Account No. 50-3013 (order no. 489808-999017).

Respectfully submitted,
Date: August 14, 2009  56,056
David C. Pauling (Reg. No.)
For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939